14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

$1.45 (-1.36%)

Volume: 201.365k

Closed: Sep 30, 2022

Hollow Logo Score: -2.812

CytomX Therapeutics Stock Forecast

$1.45 (-1.36%)

Volume: 201.365k

Closed: Sep 30, 2022

Score Hollow Logo -2.812
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSI min/max Values: [ 25 - 75 ] The CytomX Therapeutics stock currently holds an RSI14 at 23 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.
Last Reaction
Be the first to comment on CTMX

CytomX Therapeutics stock price down 1.36% on Friday
(Updated on Sep 30, 2022)


Sell candidate since 2022-09-16 Loss -8.23% PDF

The CytomX Therapeutics stock price fell by -1.36% on the last day (Friday, 30th Sep 2022) from $1.47 to $1.45. During the last trading day the stock fluctuated 4.14% from a day low at $1.45 to a day high of $1.51. The price has fallen in 5 of the last 10 days and is down by -8.23% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -43 thousand shares and in total, 201 thousand shares were bought and sold for approximately $291.98 thousand.

The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 2.26% during the next 3 months and, with a 90% probability hold a price between $1.30 and $1.79 at the end of this 3-month period.

Signals & Forecast

There are mixed signals in the stock today. The CytomX Therapeutics stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $1.57. On a fall, the stock will find some support from the short-term average at $1.44. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. A sell signal was issued from a pivot top point on Monday, August 15, 2022, and so far it has fallen -16.18%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss

CytomX Therapeutics finds support from accumulated volume at $1.40 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.0600 between high and low, or 4.14%. For the last week the stock has had daily average volatility of 4.67%.

CytomX Therapeutics is oversold on RSI14 (23). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations For The Upcoming Trading Day Of Monday 3rd

For the upcoming trading day on Monday, 3rd we expect CytomX Therapeutics to open at $1.47, and during the day (based on 14 day Average True Range), to move between $1.36 and $1.54, which gives a possible trading interval of +/-$0.0872 (+/-6.01%) up or down from last closing price. If CytomX Therapeutics takes out the full calculated possible swing range there will be an estimated 12.02% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $1.50 (3.45%) than the support at $1.40 (3.45%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is CytomX Therapeutics stock A Buy?

CytomX Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.812

Sell Candidate Unchanged

Predicted Opening Price for CytomX Therapeutics of Monday, October 3, 2022

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Fair opening price October 3, 2022 Current price
$1.47 $1.45 (Undervalued)

Remember To Visit Our YouTube Channel

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 1.53 5.52 %
1.51 3.94 %
1.49 2.96 %
Current price: 1.45
Support 1.45 -0.20 %
1.43 -1.18 %
1.41 -2.76 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 1.65 13.79 %
1.61 11.03 %
1.50 3.45 %
Current price 1.45
Support 1.40 -3.45%
1.30 -10.34%
1.23 -15.17%

Click to get the best stock tips daily for free!

Hot Stocks To Watch:

IMPROVE YOUR TRADING GAME WITH A GOLDEN STAR

From 26 676 stocks, only a few dozen will trigger such a signal!

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme... CTMX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT